Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | PNLIP | P16233 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30378054 | 1.00 | TTR (0.47) | TTRALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL29984 | 0.87 | ALDH1A1 (0.43) | TTRALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9265274 | 0.83 | TTR (0.65) | TTRALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL8683891 | 0.81 | KMT2A (0.43) | ALDH1A1SMN1; SMN2LMNAHTR2ASLC6A4 | |
| SCHEMBL8551788 | 0.81 | F2 (0.50) | TTRALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9272342 | 0.81 | MAPT (0.50) | TTRALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9762708 | 0.81 | TTR (0.42) | TTRALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL6142404 | 0.81 | TTR (0.47) | TTRALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL754458 | 0.80 | LMNA (0.45) | ALDH1A1SMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL2545532 | 0.80 | LMNA (0.45) | ALDH1A1SMN1; SMN2LMNAPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111840271-B | Novel application of glycoside derivative | 北京盈科瑞创新药物研究有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111471032-B | Synthesis method of glycoside derivative, intermediate and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-111471040-B | Synthesis method of glycoside derivative, intermediate and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-111471031-B | Glycoside derivative and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2188254-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | TTR 3260/4885ALDH1A1 2920/4885SMN1; SMN2 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.